Your email has been successfully added to our mailing list.

×
0.11340206185567 0.0618556701030927 -0.0551546391752577 -0.0927835051546392 -0.139587628865979 -0.117525773195876 -0.22680412371134 -0.175257731958763
Stock impact report

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

AlloVir, Inc. (ALVR) 
Company Research Source: GlobeNewswire
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could potentially provide a meaningful advance in treatment in the global $14 billion branded anti-VEGF retinal market TH103 is in a Phase 1 clinical trial in patients with neovascular age-related macular degeneration with initial data expected in Q3 2025 The combined company is expected to have a cash balance of approximately $100 million at close, which is anticipated in Q1 2025. Transaction expected to provide cash runway into Q4 2026 Companies to host webcast today, November 8, 2024 at 8:30 a.m. ET WALTHAM, Mass. and PALO ALTO, Calif., Nov. 08, 2024 (GLOBE Show less Read more
Impact Snapshot
Event Time:
ALVR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
ALVR alerts

from News Quantified
Opt-in for
ALVR alerts

from News Quantified